218 related articles for article (PubMed ID: 37277193)
1. Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade.
Randon G; Aoki Y; Cohen R; Provenzano L; Nasca V; Klempner SJ; Maron SB; Cerantola R; Chao J; Fornaro L; Ferrari Bravo W; Ghelardi F; Ambrosini M; Manca P; Salati M; Kawazoe A; Zhu V; Cowzer D; Genovesi V; Lonardi S; Shitara K; André T; Pietrantonio F
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37277193
[TBL] [Abstract][Full Text] [Related]
2. Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers.
Fucà G; Cohen R; Lonardi S; Shitara K; Elez ME; Fakih M; Chao J; Klempner SJ; Emmett M; Jayachandran P; Bergamo F; García MD; Mazzoli G; Provenzano L; Colle R; Svrcek M; Ambrosini M; Randon G; Shah AT; Salati M; Fenocchio E; Salvatore L; Chida K; Kawazoe A; Conca V; Curigliano G; Corti F; Cremolini C; Overman M; Andre T; Pietrantonio F
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35110358
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer.
Mazzoli G; Cohen R; Lonardi S; Corti F; Elez E; Fakih M; Jayachandran P; Colle R; Shah AT; Salati M; Fenocchio E; Salvatore L; Ambrosini M; Ros J; Intini R; Cremolini C; Overman MJ; André T; Pietrantonio F
Eur J Cancer; 2022 Sep; 172():171-181. PubMed ID: 35777274
[TBL] [Abstract][Full Text] [Related]
4. Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors.
Manca P; Corti F; Intini R; Mazzoli G; Miceli R; Germani MM; Bergamo F; Ambrosini M; Cristarella E; Cerantola R; Boccaccio C; Ricagno G; Ghelardi F; Randon G; Leoncini G; Milione M; Fassan M; Cremolini C; Lonardi S; Pietrantonio F
Eur J Cancer; 2023 Jul; 187():15-24. PubMed ID: 37099945
[TBL] [Abstract][Full Text] [Related]
5. The Prognostic Nutritional Index in patients with microsatellite instability-high metastatic gastric or gastroesophageal cancers receiving immune checkpoint inhibitors.
Ghelardi F; Fucà G; Cavalli C; Shitara K; Cohen R; Ambrosini M; Maron SB; Cerantola R; Nasca V; Liberti GD; Zambelli L; Palazzo M; Salati M; Aoki Y; Kawazoe A; Cowzer D; Lonardi S; André T; Randon G; Pietrantonio F
Dig Liver Dis; 2024 May; ():. PubMed ID: 38772790
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort.
Taïeb J; Sayah L; Heinrich K; Kunzmann V; Boileve A; Cirkel G; Lonardi S; Chibaudel B; Turpin A; Beller T; Hautefeuille V; Vivaldi C; Mazard T; Bauguion L; Niger M; Prager GW; Coutzac C; Benedikt Westphalen C; Auclin E; Pilla L
Eur J Cancer; 2023 Jul; 188():90-97. PubMed ID: 37229836
[TBL] [Abstract][Full Text] [Related]
7. Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer.
Greally M; Chou JF; Chatila WK; Margolis M; Capanu M; Hechtman JF; Tuvy Y; Kundra R; Daian F; Ladanyi M; Kelsen DP; Ilson DH; Berger MF; Tang LH; Solit DB; Diaz LA; Schultz N; Janjigian YY; Ku GY
Clin Cancer Res; 2019 Oct; 25(20):6160-6169. PubMed ID: 31337644
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors.
Li J; Deng Y; Zhang W; Zhou AP; Guo W; Yang J; Yuan Y; Zhu L; Qin S; Xiang S; Lu H; Gong J; Xu T; Liu D; Shen L
J Hematol Oncol; 2021 Jun; 14(1):95. PubMed ID: 34154614
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant Chemotherapy for Gastric Cancer Patients with Mismatch Repair Deficiency or Microsatellite Instability: Systematic Review and Meta-Analysis.
Nie RC; Chen GM; Yuan SQ; Kim JW; Zhou J; Nie M; Feng CY; Chen YB; Chen S; Zhou ZW; Wang Y; Li YF
Ann Surg Oncol; 2022 Apr; 29(4):2324-2331. PubMed ID: 34796431
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial.
Di Bartolomeo M; Morano F; Raimondi A; Miceli R; Corallo S; Tamborini E; Perrone F; Antista M; Niger M; Pellegrinelli A; Randon G; Pagani F; Martinetti A; Fucà G; Pietrantonio F;
Oncologist; 2020 Mar; 25(3):e460-e468. PubMed ID: 32162808
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of immune-checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and meta-analysis.
Kundel Y; Sternschuss M; Moore A; Perl G; Brenner B; Goldvaser H
Cancer Med; 2020 Oct; 9(20):7613-7625. PubMed ID: 32869544
[TBL] [Abstract][Full Text] [Related]
12. Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
Sati N; Boyne DJ; Cheung WY; Cash SB; Arora P
JAMA Netw Open; 2021 Jan; 4(1):e2034201. PubMed ID: 33496794
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden.
Pietrantonio F; Loupakis F; Randon G; Raimondi A; Salati M; Trapani D; Pagani F; Depetris I; Maddalena G; Morano F; Corallo S; Prisciandaro M; Corti F; Guarini V; Bocconi A; Marra A; Belli C; Spallanzani A; Fassan M; Lonardi S; Curigliano G; Fucà G; Di Bartolomeo M; de Braud F
Oncologist; 2020 Sep; 25(9):803-809. PubMed ID: 32369650
[TBL] [Abstract][Full Text] [Related]
14. RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study.
Cohen R; Bennouna J; Meurisse A; Tournigand C; De La Fouchardière C; Tougeron D; Borg C; Mazard T; Chibaudel B; Garcia-Larnicol ML; Svrcek M; Vernerey D; Menu Y; André T
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33148693
[TBL] [Abstract][Full Text] [Related]
15. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
[TBL] [Abstract][Full Text] [Related]
16. The Optimal Therapy after Progression on Immune Checkpoint Inhibitors in MSI Metastatic Gastrointestinal Cancer Patients: A Multicenter Retrospective Cohort Study.
Chen M; Wang Z; Liu Z; Liu N; Fang W; Zhang H; Jin X; Li J; Zhao W; Qu H; Song F; Chang Z; Li Y; Tang Y; Xu C; Zhang X; Wang X; Peng Z; Cai J; Li J; Shen L
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291942
[TBL] [Abstract][Full Text] [Related]
17. The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors.
Corti F; Lonardi S; Intini R; Salati M; Fenocchio E; Belli C; Borelli B; Brambilla M; Prete AA; Quarà V; Antista M; Fassan M; Morano F; Spallanzani A; Ambrosini M; Curigliano G; de Braud F; Zagonel V; Fucà G; Pietrantonio F
Eur J Cancer; 2021 Jun; 150():155-167. PubMed ID: 33901794
[TBL] [Abstract][Full Text] [Related]
18. Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer.
Pietrantonio F; Miceli R; Raimondi A; Kim YW; Kang WK; Langley RE; Choi YY; Kim KM; Nankivell MG; Morano F; Wotherspoon A; Valeri N; Kook MC; An JY; Grabsch HI; Fucà G; Noh SH; Sohn TS; Kim S; Di Bartolomeo M; Cunningham D; Lee J; Cheong JH; Smyth EC
J Clin Oncol; 2019 Dec; 37(35):3392-3400. PubMed ID: 31513484
[TBL] [Abstract][Full Text] [Related]
19. Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study.
Chen EX; Jonker DJ; Loree JM; Kennecke HF; Berry SR; Couture F; Ahmad CE; Goffin JR; Kavan P; Harb M; Colwell B; Samimi S; Samson B; Abbas T; Aucoin N; Aubin F; Koski SL; Wei AC; Magoski NM; Tu D; O'Callaghan CJ
JAMA Oncol; 2020 Jun; 6(6):831-838. PubMed ID: 32379280
[TBL] [Abstract][Full Text] [Related]
20. Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials.
Pietrantonio F; Randon G; Di Bartolomeo M; Luciani A; Chao J; Smyth EC; Petrelli F
ESMO Open; 2021 Feb; 6(1):100036. PubMed ID: 33460964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
